Department of Cardiovascular Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Europace. 2014 Jan;16(1):92-100. doi: 10.1093/europace/eut207. Epub 2013 Jul 14.
Ventricular tachycardia (VT) and ventricular fibrillation (VF) are not uncommon in patients hospitalized with acute heart failure (AHF). We sought to evaluate the efficacy of urgent radiofrequency catheter ablation (RFCA) for recurrent VT/VF during AHF decompensations.
The present study retrospectively analysed the data of 15 consecutive patients (69 ± 9 years, ischaemic heart disease in 10), who underwent urgent RFCA for frequent drug-refractory VT/VF episodes during an AHF decompensation with pulmonary congestion. The target arrhythmias were clinically documented monomorphic VTs in 10 patients, frequent premature ventricular contractions (PVCs) triggering VF in 4, and both in 1. The mean left ventricular ejection fraction was 26 ± 8%. The maximum number of arrhythmia episodes over 24 h was 9.1 ± 11.7. All RFCA sessions were completed without any major complications except for a temporary deterioration of pulmonary congestion in three patients (20%). Elimination and non-inducibility of the target arrhythmias were achieved in 13 patients (87%). Successful ablation site electrograms showed Purkinje potentials for all 5 PVCs triggering VF and 4 of 14 clinically documented monomorphic VTs (29%). Five patients (33%) underwent second sessions 10 ± 4 days after the first session for acute recurrences. Sustained VT/VF was completely suppressed during admission in 12 patients (80%), and the AHF ameliorated in 13 patients (93%). Twelve patients (80%) were discharged alive.
Urgent RFCA for drug-resistant sustained ventricular tachyarrhythmias during AHF decompensations would be an appropriate therapeutic option. Purkinje fibres can be ablation targets not only in those with PVCs triggering VF, but also in those with monomorphic VT.
在因急性心力衰竭(AHF)住院的患者中,室性心动过速(VT)和心室颤动(VF)并不少见。我们旨在评估在 AHF 失代偿期间频发药物难治性 VT/VF 时紧急进行射频导管消融(RFCA)的疗效。
本研究回顾性分析了 15 例连续患者(69 ± 9 岁,10 例缺血性心脏病)的数据,这些患者因 AHF 失代偿伴肺充血而频繁出现药物难治性 VT/VF 发作,接受了紧急 RFCA。目标心律失常在 10 例患者中为有临床记录的单形 VT,在 4 例患者中为频发室性期前收缩(PVCs)引发的 VF,在 1 例患者中为两者兼有。左心室射血分数平均为 26 ± 8%。24 小时内心律失常发作的最大次数为 9.1 ± 11.7。除 3 例患者(20%)出现短暂的肺充血恶化外,所有 RFCA 均顺利完成,无其他重大并发症。13 例患者(87%)实现了目标心律失常的消除和不可诱导性。成功消融部位的电图显示,所有 5 例引发 VF 的 PVCs 和 14 例临床记录的单形 VT 中的 4 例(29%)均显示浦肯野纤维电位。5 例患者(33%)在第一次 RFCA 后 10 ± 4 天进行了第二次 RFCA,用于急性复发。12 例患者(80%)在住院期间完全抑制持续性 VT/VF,13 例患者(93%)的 AHF 得到改善。12 例患者(80%)存活出院。
在 AHF 失代偿期间,针对药物难治性持续性室性心动过速发作,紧急进行 RFCA 可能是一种合适的治疗选择。浦肯野纤维不仅可以作为引发 VF 的 PVCs 的消融靶点,也可以作为单形 VT 的消融靶点。